Skip to main content

Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin

Buy Article:

$51.00 plus tax (Refund Policy)



We describe a patient with end-stage renal failure (ESRF) who developed anti-erythropoietin (anti-EPO) antibodies and pure red-cell aplasia (PRCA) after using Eprex (Janssen-Cilag, Sydney). Anti-EPO antibodies were detected with an immunoprecipitation technique and were shown to inhibit erythropoiesis in vitro. Antibody levels waned upon ceasing Eprex. The patient required transfusions for 21 months then recovered after immunosuppression. (Intern Med J 2003; 33: 468−471)

Keywords: antierythropoietin antibodies; end stage ­renal failure; pure red-cell aplasia; recombinant human erythropoietin

Document Type: Research Article


Affiliations: 1: Nephrology, 2: Haematology and 3: Cardiology, St. Vincent's Hospital, Sydney, New South Wales, Australia

Publication date: 2003-09-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more